Company news

ACADIA Pharmaceuticals Inc. news in 2020

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2020, newest first.

View company

Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

December 21, 2020

Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020

November 9, 2020

Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 3, 2020

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

October 25, 2020

Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020

October 20, 2020

The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”

October 13, 2020

Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors

September 30, 2020

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

September 1, 2020

ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development

August 30, 2020

ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio

August 24, 2020

ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020

August 11, 2020

ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results

August 4, 2020

ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

July 21, 2020

ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

July 19, 2020

ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

June 14, 2020

ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer

May 27, 2020

ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration

May 6, 2020

ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020

April 14, 2020

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

March 2, 2020

ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Calls in 2020

Decks in 2020